Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 20/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1822646 | 1.00 | CHRM3 (0.64) | CHRM3 | |
| Hydrochloric Acid SCHEMBL2288069 | 1.00 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL1822645 | 1.00 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL10147686 | 1.00 | CHRM3 (0.64) | CHRM3 | |
| SCHEMBL10147698 | 1.00 | CHRM3 (0.64) | CHRM3 | |
| Bromide SCHEMBL1042711 | 0.99 | CHRM3 (0.63) | CHRM3 | |
| Bromide SCHEMBL2295702 | 0.99 | CHRM3 (0.63) | CHRM3 | |
| Bromide SCHEMBL1042288 | 0.99 | CHRM3 (0.63) | CHRM3 | |
| Bromide SCHEMBL1042609 | 0.99 | CHRM3 (0.63) | CHRM3 | |
| SCHEMBL10147681 | 0.99 | CHRM3 (0.63) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2315589-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-04 | — | — | EP | disclosed |
| WO-2009139707-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139708-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190309-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST | ADRB2, ADRB1, ADRA2A | CHRM3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.